المؤلفون: Cardinali, Deborah, Beldinanzi, Marco, Ansuinelli, Michela, Elia, Loredana, Della Starza, Irene, Bellomarino, Vittorio, Matarazzo, Mabel, Di Trani, Mariangela, Cola, Mattia, Salutari, Prassede, Cedrone, Michele, Bassan, Renato, De Gobbi, Marco, Della Porta, Matteo Giovanni, De Simone, Mariacarla, Alati, Caterina, Fracchiolla, Nicola Stefano, Lunghi, Monia, Intermesoli, Tamara, Cardinali, Valeria, Mulè, Antonino, Guarini, Anna, Foà, Robin, Chiaretti, Sabina

المساهمون: Cardinali, Deborah, Beldinanzi, Marco, Ansuinelli, Michela, Elia, Loredana, Della Starza, Irene, Bellomarino, Vittorio, Matarazzo, Mabel, Di Trani, Mariangela, Cola, Mattia, Salutari, Prassede, Cedrone, Michele, Bassan, Renato, De Gobbi, Marco, Della Porta, Matteo Giovanni, De Simone, Mariacarla, Alati, Caterina, Fracchiolla, Nicola Stefano, Lunghi, Monia, Intermesoli, Tamara, Cardinali, Valeria, Mulè, Antonino, Guarini, Anna, Foà, Robin, Chiaretti, Sabina

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37452789; firstpage:1; lastpage:4; numberofpages:4; journal:LEUKEMIA & LYMPHOMA; https://hdl.handle.net/2318/1924511Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85165314455

الإتاحة: https://doi.org/10.1080/10428194.2023.2235450Test
https://hdl.handle.net/2318/1924511Test

المؤلفون: Oliva, Esther Natalie, Candoni, Anna, Salutari, Prassede, Palumbo, Giuseppe A., Reda, Gianluigi, Iannì, Giuseppe, Tripepi, Giovanni, Cuzzola, Maria, Capelli, Debora, Mammì, Corrado, Alati, Caterina, Cannatà, Maria Concetta, Niscola, Pasquale, Serio, Bianca, Musto, Pellegrino, Vigna, Ernesto, Volpe, Antonio, Melillo, Lorella Maria Antonia, Arcadi, Maria Teresa, Mannina, Donato, Zannier, Maria Elena, Latagliata, Roberto

المساهمون: Oliva, Esther Natalie, Candoni, Anna, Salutari, Prassede, Palumbo, Giuseppe A., Reda, Gianluigi, Iannì, Giuseppe, Tripepi, Giovanni, Cuzzola, Maria, Capelli, Debora, Mammì, Corrado, Alati, Caterina, Cannatà, Maria Concetta, Niscola, Pasquale, Serio, Bianca, Musto, Pellegrino, Vigna, Ernesto, Volpe, Antonio, Melillo, Lorella Maria Antonia, Arcadi, Maria Teresa, Mannina, Donato, Zannier, Maria Elena, Latagliata, Roberto

مصطلحات موضوعية: acute myeloid leukemia, azacitidine, elderly, post-remission therapy

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000991562000001; volume:15; issue:9; firstpage:2441; lastpage:2458; journal:CANCERS; https://hdl.handle.net/11380/1303166Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85159213732

الإتاحة: https://doi.org/10.3390/cancers15092441Test
https://hdl.handle.net/11380/1303166Test

المؤلفون: Todisco, Elisabetta, Papayannidis, Cristina, Fracchiolla, Nicola, Petracci, Elisabetta, Zingaretti, Chiara, Vetro, Calogero, Martelli, Maria Paola, Zappasodi, Patrizia, Di Renzo, Nicola, Gallo, Susanna, Audisio, Ernesta, Griguolo, Davide, Cerchione, Claudio, Selleri, Carmine, Mattei, Daniele, Bernardi, Massimo, Fumagalli, Monica, Rizzuto, Giuliana, Facchini, Luca, Basilico, Claudia Maria, Manfra, Ilenia, Borlenghi, Erika, Cairoli, Roberto, Salutari, Prassede, Gottardi, Michele, Molteni, Alfredo, Martini, Vincenza, Lunghi, Monia, Fianchi, Luana, Cilloni, Daniela, Lanza, Francesco, Abruzzese, Elisabetta, Cascavilla, Nicola, Rivellini, Flavia, Ferrara, Felicetto, Maurillo, Luca, Nanni, Jacopo, Romano, Alessandra, Cardinali, Valeria, Gigli, Federica, Roncoroni, Elisa, Federico, Vincenzo, Marconi, Giovanni, Volpi, Roberta, Sciumè, Mariarita, Tarella, Corrado, Rossi, Giuseppe, Martinelli, Giovanni

المساهمون: Todisco, Elisabetta, Papayannidis, Cristina, Fracchiolla, Nicola, Petracci, Elisabetta, Zingaretti, Chiara, Vetro, Calogero, Martelli, Maria Paola, Zappasodi, Patrizia, Di Renzo, Nicola, Gallo, Susanna, Audisio, Ernesta, Griguolo, Davide, Cerchione, Claudio, Selleri, Carmine, Mattei, Daniele, Bernardi, Massimo, Fumagalli, Monica, Rizzuto, Giuliana, Facchini, Luca, Basilico, Claudia Maria, Manfra, Ilenia, Borlenghi, Erika, Cairoli, Roberto, Salutari, Prassede, Gottardi, Michele, Molteni, Alfredo, Martini, Vincenza, Lunghi, Monia, Fianchi, Luana, Cilloni, Daniela, Lanza, Francesco, Abruzzese, Elisabetta, Cascavilla, Nicola, Rivellini, Flavia, Ferrara, Felicetto, Maurillo, Luca, Nanni, Jacopo, Romano, Alessandra, Cardinali, Valeria, Gigli, Federica, Roncoroni, Elisa, Federico, Vincenzo, Marconi, Giovanni, Volpi, Roberta, Sciumè, Mariarita, Tarella, Corrado, Rossi, Giuseppe, Martinelli, Giovanni

مصطلحات موضوعية: acute myeloid leukemia, hypomethylating agent, real-life data, relapsed and refractory AML, venetoclax

الوصف: Background: Venetoclax in combination with hypomethylating agents (HMA) is revolutionizing the therapy of acute myeloid leukemia (AML). However, evidence on large sets of patients is lacking, especially in relapsed or refractory leukemia. Methods: AVALON is a multicentric cohort study that was conducted in Italy on patients with AML who received venetoclax-based therapies from 2015 to 2020. The study was approved by the ethics committee of the participating institution and was conducted in accordance with the Declaration of Helsinki. The effectiveness and toxicity of venetoclax+HMA in 190 (43 newly diagnosed, 68 refractory, and 79 relapsed) patients with AML are reported here. Results: In the newly diagnosed AML, the overall response rate and survival confirmed the brilliant results demonstrated in VIALE-A. In the relapsed or refractory AML, the combination demonstrated a surprisingly complete remission rate (44.1% in refractory and 39.7% in relapsed evaluable patients) and conferred to treated patients a good expectation of survival. Toxicities were overall manageable, and most incidents occurred in the first 60days of therapy. Infections were confirmed as the most common nonhematologic adverse event. Conclusions: Real-life data show that the combination of venetoclax and HMA offers an expectation of remission and long-term survival to elderly, newly diagnosed patients, and to relapsed or chemoresistant AML, increasing the chance of cure through a different mechanism of action. The venetoclax+HMA combination is expected to constitute the base for triplet combinations and integration of target therapies. Our data contribute to ameliorate the understanding of venetoclax+HMA effectiveness and toxicities in real life.

وصف الملف: ELETTRONICO

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36692409; info:eu-repo/semantics/altIdentifier/wos/WOS:000922751100001; volume:online; firstpage:1; lastpage:13; numberofpages:13; journal:CANCER; https://hdl.handle.net/11585/918464Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85147305218

الإتاحة: https://doi.org/10.1002/cncr.34608Test
https://hdl.handle.net/11585/918464Test

المؤلفون: Oliva, Esther Natalie, Riva, Marta, Niscola, Pasquale, Santini, Valeria, Breccia, Massimo, Giai, Valentina, Poloni, Antonella, Patriarca, Andrea, Crisà, Elena, Capodanno, Isabella, Salutari, Prassede, Reda, Gianluigi, Cascavilla, Nicola, Ferrero, Dario, Guarini, Attilio, Tripepi, Giovanni, Iannì, Giuseppe, Russo, Emilio, Castelli, Andrea, Fattizzo, Bruno, Beltrami, Germana, Bocchia, Monica, Molteni, Alfredo, Fenaux, Pierre, Germing, Ulrich, Ricco, Alessandra, Palumbo, Giuseppe A, Impera, Stefana, Di Renzo, Nicola, Rivellini, Flavia, Buccisano, Francesco, Stamatoullas-Bastard, Aspasia, Liberati, Anna Marina, Candoni, Anna, Delfino, Ilaria Maria, Arcadi, Maria Teresa, Cufari, Patrizia, Rizzo, Lorenzo, Bova, Irene, D'Errigo, Maria Grazia, Zini, Gina, Latagliata, Roberto

المساهمون: Oliva, Esther Natalie, Riva, Marta, Niscola, Pasquale, Santini, Valeria, Breccia, Massimo, Giai, Valentina, Poloni, Antonella, Patriarca, Andrea, Crisà, Elena, Capodanno, Isabella, Salutari, Prassede, Reda, Gianluigi, Cascavilla, Nicola, Ferrero, Dario, Guarini, Attilio, Tripepi, Giovanni, Iannì, Giuseppe, Russo, Emilio, Castelli, Andrea, Fattizzo, Bruno, Beltrami, Germana, Bocchia, Monica, Molteni, Alfredo, Fenaux, Pierre, Germing, Ulrich, Ricco, Alessandra, Palumbo, Giuseppe A, Impera, Stefana, Di Renzo, Nicola, Rivellini, Flavia, Buccisano, Francesco, Stamatoullas-Bastard, Aspasia, Liberati, Anna Marina, Candoni, Anna, Delfino, Ilaria Maria, Arcadi, Maria Teresa, Cufari, Patrizia, Rizzo, Lorenzo, Bova, Irene, D'Errigo, Maria Grazia, Zini, Gina, Latagliata, Roberto

الوصف: Purpose: In myelodysplastic syndromes (MDS), severe thrombocytopenia is associated with poor prognosis. This multicenter trial presents the second-part long-term efficacy and safety results of eltrombopag in patients with low-risk MDS and severe thrombocytopenia. Methods: In this single-blind, randomized, placebo-controlled, phase-II trial of adult patients with International Prognostic Scoring System low- or intermediate-1-risk MDS, patients with a stable platelet (PLT) count (<30 × 103/mm3) received eltrombopag or placebo until disease progression. Primary end points were duration of PLT response (PLT-R; calculated from the time of PLT-R to date of loss of PLT-R, defined as bleeding/PLT count <30 × 103/mm3 or last date in observation) and long-term safety and tolerability. Secondary end points included incidence and severity of bleeding, PLT transfusions, quality of life, leukemia-free survival, progression-free survival, overall survival and pharmacokinetics. Results: From 2011 to 2021, of 325 patients screened, 169 patients were randomly assigned oral eltrombopag (N = 112) or placebo (N = 57) at a starting dose of 50 mg once daily to maximum of 300 mg. PLT-R, with 25-week follow-up (IQR, 14-68) occurred in 47/111 (42.3%) eltrombopag patients versus 6/54 (11.1%) in placebo (odds ratio, 5.9; 95% CI, 2.3 to 14.9; P < .001). In eltrombopag patients, 12/47 (25.5%) lost the PLT-R, with cumulative thrombocytopenia relapse-free survival at 60 months of 63.6% (95% CI, 46.0 to 81.2). Clinically significant bleeding (WHO bleeding score ≥ 2) occurred less frequently in the eltrombopag arm than in the placebo group (incidence rate ratio, 0.54; 95% CI, 0.38 to 0.75; P = .0002). Although no difference in the frequency of grade 1-2 adverse events (AEs) was observed, a higher proportion of eltrombopag patients experienced grade 3-4 AEs (χ2 = 9.5, P = .002). AML evolution and/or disease progression occurred in 17% (for both) of eltrombopag and placebo patients with no difference in survival times. Conclusion: ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37294914; info:eu-repo/semantics/altIdentifier/wos/WOS:001081587100008; firstpage:1; lastpage:12; journal:JOURNAL OF CLINICAL ONCOLOGY; https://hdl.handle.net/11380/1307166Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85167855884

الإتاحة: https://doi.org/10.1200/JCO.22.02699Test
https://hdl.handle.net/11380/1307166Test

المؤلفون: Fracchiolla, Nicola Stefano, Sciumè, Mariarita, Papayannidis, Cristina, Vitale, Antonella, Chiaretti, Sabina, Annunziata, Mario, Giglio, Fabio, Salutari, Prassede, Forghieri, Fabio, Lazzarotto, Davide, Lunghi, Monia, Imovilli, Annalisa, Scappini, Barbara, Bonifacio, Massimiliano, Dargenio, Michelina, Gurrieri, Carmela, Todisco, Elisabetta, Defina, Marzia, Del Principe, Maria Ilaria, Zappasodi, Patrizia, Cerrano, Marco, Santoro, Lidia, Tagliaferri, Elena, Barozzi, Enrico, De Roberto, Pasquale, Canzi, Marta, Buzzatti, Elisa, Sartor, Chiara, Passamonti, Francesco, Foà, Robin, Curti, Antonio

المساهمون: Fracchiolla, N, Sciumè, M, Papayannidis, C, Vitale, A, Chiaretti, S, Annunziata, M, Giglio, F, Salutari, P, Forghieri, F, Lazzarotto, D, Lunghi, M, Imovilli, A, Scappini, B, Bonifacio, M, Dargenio, M, Gurrieri, C, Todisco, E, Defina, M, Del Principe, Mi, Zappasodi, P, Cerrano, M, Santoro, L, Tagliaferri, E, Barozzi, E, De Roberto, P, Canzi, M, Buzzatti, E, Sartor, C, Passamonti, F, Foà, R, Curti, A

مصطلحات موضوعية: acute lymphoblastic leukemia, blinatumomab, immunotherapy, inotuzumab ozogamicin, Settore MED/15

الوصف: Background: blinatumomab (blina) and inotuzumab ozogamicin (InO) has improved the outcome of relapsed/refractory B-lymphoblastic leukemia (R/R B-ALL). however, little is known about the outcome after recurrence and re-treatment with immunotherapy. methods: we describe 71 R/R B-ALL patients treated for different relapses with blina and InO. blina was the first treatment in 57 patients and InO in 14. twenty-seven patients had a previous allogeneic hematopoietic stem cell transplantation (allo-HSCT). Results: In the Blina/InO group, after Blina, 36 patients (63%) achieved a complete remission (CR), with 42% of negative minimal residual disease (MRD-); after InO, a CR was achieved in 47 patients (82%, 34 MRD-). In the InO/blina group, after InO, 13 cases (93%) reached a CR (6 MRD-); after Blina, a CR was re-achieved in 6 cases (43%, 3 MRD-). Twenty-six patients proceeded to allo-HSCT. In the blina/InO group, the median overall survival (OS) was 19 months; the disease-free survival (DFS) after blina was 7.4 months (11.6 vs. 2.7 months in MRD- vs. MRD+, p = 0.03) and after InO, 5.4 months. In the InO/Blina group, the median OS was 9.4 months; the median DFS after InO was 5.1 months and 1.5 months after Blina (8.7 vs. 2.5 months in MRD- vs. MRD+, p = 0.02). With a median follow-up of 16.5 months from the start of immunotherapy, 24 patients (34%) are alive and 16 (22%) are alive in CR. Conclusion: In our series of R/R B-ALL, Blina and InO treatment demonstrate efficacy for subsequent relapses in terms of MRD response, OS and DFS, and as a bridge to allo-HSCT.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37760592; info:eu-repo/semantics/altIdentifier/wos/WOS:001071337500001; volume:15; issue:18; firstpage:4623; journal:CANCERS; https://hdl.handle.net/2108/340344Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85172778878

الإتاحة: https://doi.org/10.3390/cancers15184623Test
https://hdl.handle.net/2108/340344Test

المؤلفون: Oswald, Laura B, Venditti, Adriano, Cella, David, Cottone, Francesco, Candoni, Anna, Melillo, Lorella, Cairoli, Roberto, Storti, Gabriella, Salutari, Prassede, Luppi, Mario, Albano, Francesco, Martelli, Maria Paola, Cuneo, Antonio, Tafuri, Agostino, Trisolini, Silvia Maria, Tieghi, Alessia, Fazi, Paola, Vignetti, Marco, Efficace, Fabio

مصطلحات موضوعية: Original research

الوصف: Objectives This study compared the burden of fatigue between treatment-nai&x0308;ve patients with newly diagnosed acute myeloid leukaemia (AML) and the general population and investigated patient factors associated with fatigue severity. Methods Pretreatment patient-reported fatigue was assessed with the Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire in a sample of 463 newly diagnosed patients with AML who were enrolled in a clinical trial. Multivariable linear regression models were used to estimate the adjusted mean differences in fatigue between patients with AML and adults from the general population (n=847) by AML disease risk categories. A clinically meaningful difference in fatigue was defined as ≥3 points. Univariable and multivariable linear regression models were used to identify sociodemographic, clinical and molecular correlates of worse fatigue in patients with AML. Results Patients with AML reported adjusted mean fatigue scores that were 7.5 points worse than the general population (95% CI −8.6 to −6.4, p<0.001). Across AML disease risk categories, adjusted mean differences in fatigue compared with the general population ranged from 6.7 points worse (patients with favourable risk: 95% CI −8.6 to −4.8, p<0.001) to 8.9 points worse (patients with poor risk, 95% CI −10.5 to −7.2, p<0.001). Overall, 91% of patients with AML reported fatigue that was equal to or worse than the general population’s median fatigue score. Higher pretreatment fatigue was independently associated with female sex, WHO performance status ≥1 and lower platelet levels. Conclusions Patients with newly diagnosed AML reported worse fatigue than the general population, and mean differences exceeded twice the threshold for clinical significance. Our findings may help to identify patients with AML most likely to benefit from supportive care interventions to reduce fatigue.

وصف الملف: text/html

العلاقة: http://spcare.bmj.com/cgi/content/short/13/e2/e344Test; http://dx.doi.org/10.1136/bmjspcare-2020-002312Test

الإتاحة: https://doi.org/10.1136/bmjspcare-2020-002312Test
http://spcare.bmj.com/cgi/content/short/13/e2/e344Test

المؤلفون: Oliva, Esther, Iannì, Giuseppe, Riva, Marta, Niscola, Pasquale, Santini, Valeria, Breccia, Massimo, Gaidano, Valentina, Poloni, Antonella, Patriarca, Andrea, Crisà, Elena, Capodanno, Isabella, Salutari, Prassede, Reda, Gianluigi, Sanpaolo, Grazia, Ferrero, Dario, Guarini, Attilio, Tripepi, Giovanni, Castelli, Andrea, Fattizzo, Bruno, Beltrami, Germana, Bocchia, Monica, Molteni, Alfredo, Fenaux, Pierre, Germing, Ulrich, Ricco, Alessandra, Palumbo, Giuseppe A., Impera, Stefana, Renzo, Nicola DI, Buccisano, Francesco, Stamatoullas, Aspasia, Liberati, Anna Marina, Candoni, Anna, Delfino, Ilaria Maria, Cufari, Patrizia, Rizzo, Lorenzo, Latagliata, Roberto

المصدر: HemaSphere ; volume 7, issue S3, page e44846cb ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000977356.44846.cbTest

المؤلفون: Venditti, Adriano, Piciocchi, Alfonso, Maurillo, Luca, Ilaria Del Principe, Maria, Palmieri, Raffaele, Soddu, Stefano, Moretti, Federico, Salutari, Prassede, Martelli, Maurizio, Paola Martelli, Maria, Luppi, Mario, Pulsoni, Alessandro, Zaja, Francesco, Cairoli, Roberto, Pane, Fabrizio, Siragusa, Sergio, Bassan, Renato, Rondoni, Michela, Mirabile, Milena, Mulè, Antonino, Beltrami, Germana, Zappasodi, Patrizia, Cudillo, Laura, Mengarelli, Andrea, Curti, Antonio, Ferrara, Felicetto, Rossi, Giovanni, Audisio, Ernesta, Spinosa, Giuseppina, Tieghi, Alessia, Bocchia, Monica, Martini, Vincenza, Califano, Catello, Rigacci, Luigi, Tafuri, Agostino, Gottardi, Michele, Fazi, Paola, Vignetti, Marco, Buccisano, Francesco

المصدر: HemaSphere ; volume 7, issue S3, page e8415389 ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000968928.84153.89Test

المؤلفون: Kayser, Sabine, Sartor, Chiara, Giglio, Fabio, Bruno, Alessandro, Webster, Jonathan, Chiusolo, Patrizia, Saraceni, Francesco, Guerzoni, Selene, Pochintesta, Lara, Borlenghi, Erika, Marconi, Giovanni, Zacheo, Irene, Cerrano, Marco, Salutari, Prassede, Restuccia, Francesco, Abbenante, Mariachiara, J Levis, Mark, Schlenk, Richard, Papayannidis, Cristina

المصدر: HemaSphere ; volume 7, issue S3, page e9701805 ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000968412.97018.05Test

المؤلفون: Pennese, Elsa, Salutari, Prassede, Carriero, Luigi, Restuccia, Francesco, De Filippis, Antonio Fabio, De Luca, Giulia, Giancola, Raffaella, Guardalupi, Francesco, Corradi, Giulia, Fabi, Bianca, Baldoni, Stefano, Di Ianni, Mauro

المصدر: Frontiers in Immunology ; volume 14 ; ISSN 1664-3224

مصطلحات موضوعية: Immunology, Immunology and Allergy

الوصف: CAR-T therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies. Patients who are receiving such therapy are susceptible to an increased incidence of infections due to post-treatment immunosuppression. The need for antifungal prophylaxis during the period of neutropenia remains to be determined. The clinical outcome of a 55-year-old patient with relapsed/refractory DLBCL who received axicabtagene ciloleucel is described here. The patient developed CRS grade II and ICANS grade IV requiring tocilizumab, prolonged use of steroids and anakinra. An invasive pulmonary aspergillosis arose after 1 month from CAR-T reinfusion, resolved with tracheal sleeve pneumonectomy. The patient is now in Complete Remission. This case suggests that antifungal prophylaxis should be considered. We have now included micafungin as a standard prophylaxis in our institution.

الإتاحة: https://doi.org/10.3389/fimmu.2023.1272798Test